866-997-4948(US-Canada Toll Free)

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Jan 2018

Category :

Pharmaceutical

No. of Pages : 155 Pages

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2018, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 8, 7, 12, 3 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hospital Acquired Pneumonia (HAP) - Overview 6
Hospital Acquired Pneumonia (HAP) - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 11
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 23
Adenium Biotech ApS 23
Aridis Pharmaceuticals LLC 23
AstraZeneca Plc 24
Cardeas Pharma Corp 24
Centauri Therapeutics Ltd 24
CytaCoat AB 25
Destiny Pharma Ltd 25
Dong-A Socio Holdings Co Ltd 26
Lakewood-Amedex Inc 26
MedImmune LLC 27
Meiji Seika Pharma Co Ltd 27
Melinta Therapeutics Inc 27
Merck & Co Inc 28
Motif Bio Plc 29
Nabriva Therapeutics plc 29
Polyphor Ltd 29
Sealife PHARMA GMBH 30
Shionogi & Co Ltd 30
Tetraphase Pharmaceuticals Inc 31
Theravance Biopharma Inc 31
Wockhardt Ltd 32
Zavante Therapeutics Inc 32
Hospital Acquired Pneumonia (HAP) - Drug Profiles 34
(avibactam + ceftazidime) - Drug Profile 34
(cefepime + zidebactam) - Drug Profile 39
(ceftolozane sulfate + tazobactam sodium) - Drug Profile 40
(cilastatin sodium + imipenem + relebactam) - Drug Profile 46
(meropenem + vaborbactam) - Drug Profile 48
AA-139 - Drug Profile 55
Aerucin - Drug Profile 56
alalevonadifloxacin - Drug Profile 58
amikacin sulfate + fosfomycin - Drug Profile 60
AR-401 - Drug Profile 62
arbekacin - Drug Profile 63
ASN-100 - Drug Profile 64
cefiderocol sulfate tosylate - Drug Profile 67
EBX-004 - Drug Profile 72
eravacycline - Drug Profile 73
exeporfinium chloride - Drug Profile 82
fosfomycin tromethamine - Drug Profile 85
iclaprim - Drug Profile 89
lefamulin acetate - Drug Profile 96
levonadifloxacin - Drug Profile 102
MEDI-3902 - Drug Profile 103
Mul-1867 - Drug Profile 104
murepavadin - Drug Profile 106
Nu-2 - Drug Profile 109
Nu-3 - Drug Profile 110
Panaecin - Drug Profile 112
panobacumab - Drug Profile 113
POL-7001 - Drug Profile 115
Polysaccharides for Hospital Acquired Pneumonia - Drug Profile 116
Qn-2251 - Drug Profile 117
SLP-0905 - Drug Profile 118
Small Molecules for Bacterial Infections, Ventilator Associated Pneumonia, Sepsis and Surgical Wound Infections - Drug Profile 119
sodium hypochlorite - Drug Profile 120
suvratoxumab - Drug Profile 121
tedizolid phosphate - Drug Profile 122
telavancin hydrochloride - Drug Profile 130
tosatoxumab - Drug Profile 136
Hospital Acquired Pneumonia (HAP) - Dormant Projects 138
Hospital Acquired Pneumonia (HAP) - Discontinued Products 139
Hospital Acquired Pneumonia (HAP) - Product Development Milestones 140
Featured News & Press Releases 140
Appendix 151
Methodology 151
Coverage 151
Secondary Research 151
Primary Research 151
Expert Panel Validation 151
Contact Us 151
Disclaimer 152

List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics plc, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H1 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H1 2018
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2018
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *